Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04798469 · ClinicalTrials.gov registry record · Phase 2
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
A Phase 2 study of Pain and Opioid Use, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT04798469: Recruiting Phase 2 study of Pain and Opioid Use, sponsored by Brigham and Women's Hospital.
NCT04798469 is a Phase 2 study of Pain and Opioid Use that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 150 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04798469, a Phase 2 study of Pain and Opioid Use, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism (low testosterone).
Primary Outcome
The Pain Interference Subscale of the BPI is specifically relevant to patients with chronic back pain who are using opioids and correlates strongly with the patient's quality of life.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Testosterone Undecanoate 250 MG/ML
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 2 |
What NCT04798469 shows while recruiting
NCT04798469 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04798469 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04798469 about?
NCT04798469 is a clinical study titled "Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism". The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism ...
What is the current status of trial NCT04798469?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2022-01-10. Estimated completion is 2027-12-30.
What conditions does trial NCT04798469 study?
This clinical trial studies the following conditions: Pain, Opioid Use, Hypogonadism, Male.
What interventions are being tested in trial NCT04798469?
The interventions under investigation include: Placebo (DRUG), Testosterone Undecanoate 250 MG/ML (DRUG).
Who is sponsoring clinical trial NCT04798469?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04798469 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04798469's enrollment target sits among peer trials
150 114th of 374 higher than 255 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
-
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI